ATTR-ACT LONG-TERM EXTENSION STUDY POINTS TO BETTER SURVIVAL OUTCOMES WITH TAFAMIDIS

The recent ATTR-ACT long-term extension (LTE) study concluded that patients initially treated with tafamidis had significantly better survival than those initially treated with placebo, highlighting the significance of early diagnosis and treatment in transthyretin amyloid cardiomyopathy (ATTR-CM).